Study results of Medtronic DBS Therapy for epilepsy published in Epilepsia

Mar 19 2010

Medtronic, Inc. (NYSE:MDT) today announced that a landmark publication highlighting results from the pivotal study for Medtronic Deep Brain Stimulation (DBS) Therapy for epilepsy, known as SANTE® (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy), was published online today in the medical journal, Epilepsia. The SANTE study, sponsored by Medtronic, is the largest and most rigorous clinical study of DBS therapy for epilepsy in adults with medically refractory epilepsy with partial-onset seizures. Today’s publication includes results from the blinded phase of the study and through two years of therapy. Medtronic DBS therapy is under review by the U.S. Food and Drug Administration (FDA).

“The SANTE trial was a rigorous, well-designed, blinded trial with long-term follow up in an open-label phase. Based on the outcome of the study, DBS therapy holds promise for patients with epilepsy who are severely affected and have not had success with other treatments”

“The SANTE trial was a rigorous, well-designed, blinded trial with long-term follow up in an open-label phase. Based on the outcome of the study, DBS therapy holds promise for patients with epilepsy who are severely affected and have not had success with other treatments,” said Robert Fisher, M.D., professor of neurology and director of Stanford Epilepsy Center, principal investigator for the SANTE study and lead author of today’s publication.